Literature DB >> 19473614

Prevalence of hypercalcitoninemia in patients on maintenance dialysis referred to kidney transplantation.

B Akan1, G Böhmig, G Sunder-Plassmann, K A Borchhardt.   

Abstract

AIMS: Elevated calcitonin concentrations in dialysis patients had led to thyroidectomy for a benign C-cell hyperplasia in dozens of patients in the past decade. The prevalence of hypercalcitoninemia, however, has not been examined in a large cohort of dialysis patients.
METHODS: We, therefore, measured calcitonin concentrations in 283 dialysis patients. We used different reference intervals: according to the threshold to perform further stimulation tests (i.e. > 10 pg/ml) and new reference intervals for the currently used assay (i.e. serum calcitonin concentration < 11.5 pg/ml in men and < 4.6 pg/ml in women).
RESULTS: Median calcitonin concentrations of men and women were 12 (1; 290) pg/ml vs 2 pg/ml (1; 45), respectively, (p < 0.0001). The prevalence of hypercalcitoninemia was 10% in women and 58% in men using a cut-off of 10 pg/ml. Applying the new reference intervals 31% of women and 54% of men presented with hypercalcitoninemia. All patients with basal calcitonin concentrations above 50 pg/ml were men (highest calcitonin concentration was 290 pg/ml). Two of them underwent thyroidectomy and had C-cell hyperplasia.
CONCLUSION: The prevalence of hypercalcitoninemia in dialysis patients amounts to 46%. It is more common in male than in female dialysis patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473614     DOI: 10.5414/cnp71538

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  Serum calcitonin and endothelial dysfunction in chronic kidney disease: a novel risk factor?

Authors:  Mehmet Kanbay; Mahmut Ilker Yilmaz; Baris Afsar; Mutlu Saglam; Emin Ozgur Akgul; Tuncer Cayci; Kayser Caglar; Hilmi Umut Unal; Mahmut Gok; Abdulgaffar Vural; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2012-03-23       Impact factor: 2.370

2.  Development and application of a novel sensitive immunometric assay for calcitonin in a large cohort of patients with medullary and differentiated thyroid cancer, thyroid nodules, and autoimmune thyroid diseases.

Authors:  Cléber P Camacho; Susan C Lindsey; Teresa S Kasamatsu; Alberto L Machado; João Roberto M Martins; Rosa Paula M Biscolla; Magnus R Dias da Silva; José Gilberto H Vieira; Rui M B Maciel
Journal:  Eur Thyroid J       Date:  2014-06-18

3.  Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease.

Authors:  Mehmet Kanbay; Myles Wolf; Yusuf Selcoki; Yalcin Solak; Mustafa Ikizek; Sema Uysal; Liviu Segall; Ferah Armutcu; Beyhan Eryonucu; Murat Duranay; David Goldsmith; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2011-12-01       Impact factor: 2.370

4.  Hot flushes, hypertension and haemodialysis.

Authors:  Janak R de Zoysa; Alvin K H Ng; David D W Kim; Isaac M Cranshaw; Michael S Croxson
Journal:  NDT Plus       Date:  2011-01-27

5.  LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

Authors:  G H Daniels; L Hegedüs; S P Marso; M A Nauck; B Zinman; R M Bergenstal; J F E Mann; J Derving Karsbøl; A C Moses; J B Buse; R M Tuttle
Journal:  Diabetes Obes Metab       Date:  2015-02-23       Impact factor: 6.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.